Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2019

Open Access 01-12-2019 | Edema | Case report

Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series

Authors: Zhongjing Lin, Qiwei Hu, Yanlin Wu, Jianmin Xu, Qiong Zhang

Published in: BMC Ophthalmology | Issue 1/2019

Login to get access

Abstract

Background

There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the clinical efficacy of intravitreal ranibizumab or intravitreal conbercept for retinal arterial macroaneurysm.

Case presentation

Three cases that presented with symptomatic RAM were treated with intravitreal anti-VEGF agents. Two eyes received two intravitreal ranibizumab injections with a time interval of one month and completed a one-year follow-up, while one eye only received one intravitreal conbercept injection and was followed up for six months. Both the retinal thickness and the visual acuity were significantly improved at the final clinic visit. The macular hemorrhage and edema were resolved. There were no ocular or systemic side effects.

Conclusions

Intravitreal ranibizumab or conbercept might be used as a therapeutic option for symptomatic retinal arterial macroaneurysm patients. Anti-VEGF therapy should be further investigated in a larger series with longer follow-up for this disease profile.
Literature
1.
Robertson DM. Macroaneurysms of the retinal arteries. Trans Am Acad Ophthalmol Otolaryngol. 1973;77(1):55–67.
2.
Addel-Khalek MN, Richardson J. Retinal macroaneurysm: natural history and guidelines for treatment. Br J Ophthalmol. 1986;70(1):2–11.CrossRef
3.
Rabb MF, Gagliano DA, Teske MP. Retina arterial macroaneurysms. Surv Ophthalmol. 1988;33(2):73–96.CrossRef
4.
McCabe CM, Flynn HW Jr, Mclean WC, et al. Nonsurgical management of macular hemorrhage secondary to retinal artery macroaneurysms. Arch Ophthaolmol. 2000;118(6):780–5.CrossRef
5.
Contreras JE, Mittra RB, Mieler WF, Pollack JS. Retina arterial macroaneurysms. In: Yanoff M, Duker JS, editors. Ophthalmology. 2nd ed. Philadelphia: Mosby Elsevier; 2004. p. 912–7.
6.
Cahuzac A, Scemama C, Mauget-Faÿsse M, Sahel JA, Wolff B. Retinal arterial macroaneurysms: clinical, angiographic, and tomographic description and therapeutic management of a series of 14 case. Eur J Ophthalmol. 2016;26(1):36–43.CrossRef
7.
Pitkänen L, Tommila P, Kaarniranta K, Jääskeläinen JE, Kinnunen K. Retinal arterial macroaneurysms. Acta Ophthalmol. 2014;92(2):101–4.CrossRef
8.
Pichi F, Morara M, Torrazza C, et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurtsms. Am J Ophthalmol. 2013;155(2):287–94.CrossRef
9.
Cho HJ, Rhee TK, Kim HS, Han JI, Lee DW, Cho SW, Kim JW. Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm. Am J Ophthalmol. 2013;155(5):898–904.CrossRef
10.
Oztas Z, Nalcaci S, Akkin C. Intravitreal aflibercept for ruptured retinal arterial macroaneurysm. Int J Ophthalmol. 2017;10(3):491–3.PubMedPubMedCentral
11.
Speilburg AM, Klemencic SA. Ruptured retinal arterial macroaneurysm: diagnosis and management. J Optom. 2014;7(3):131–7.CrossRef
12.
Maltsev DS, Kulikov AN, Uplanchiwar B, Lima LH, Chhablani J. Direct navigated laser photocoagulation as primary treatment for retinal arterial macroaneurysms. Int J Retina Vitreous. 2018;4:28.CrossRef
13.
Chanana B, Azad RV. Intrvitreal bevacizumab for macular edema secondary to retinal arterial macroaneurysm. Eye(Lond). 2009;23(2):493–4.
14.
Bormann C, Heichel J, Hammer U, Habetmann A, Hammer T. Intravitreal anti-vascualr endothelial growth factor for macular edema due to complex retinal arterial macroaneurysms. Case Rep Ophthalmol. 2017;8(1):137–43.CrossRef
15.
Erol MK, Dogan B, Coban DT, Toslak D, Cengiz A, Ozel D. Intravitreal ranbiuzumab therapy for retinal arterial macroaneurysm. Int J Clin Med. 2015;8(7):11572–8.
16.
Zweifel SA, Tönz MS, Pfenniger L, et al. Intravitreal anti-VEGF therapy for retinal macroaneurysm. Klin Monbl Augenheilked. 2013;230:392–5.CrossRef
17.
Kishore K. Long-term management of complications of retinal artery macroaneurysms with intravitreal aflibercept injection. Case Rep Ophthalmol. 2016;7(3):162–71.CrossRef
18.
Zhang M, Zhang J, Yan M, et al. A phase I study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology. 2011;118(4):672–8.CrossRef
19.
Su L, Ren X, Wei H, et al. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina. 2016;36(5):938–43.CrossRef
20.
de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int Retina Vitr. 2016;2:3.CrossRef
21.
Cui J, Sun D, Lu H, et al. Comparision of effectiveness and safety between conbercept and ranibizumab for treatment of neovasuclar age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye(Lond). 2018;32(2):391–9.PubMed
22.
Yang X, Xu J, Wang R, et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. J Ophthalmol. 2016;2016:2473234.PubMedPubMedCentral
23.
Qu J, Cheng Y, Li X, Yu L, Ke X, AURORA Study Group. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy. Retina. 2016;36(5):926–37.CrossRef
24.
Jin E, Yin H, Li X, Zhao M. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina. 2018;38(8):1595–604.CrossRef
25.
Sun Z, Zhou H, Lin B, et al. Efficacy and safety intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina. 2017;37(9):1723–30.CrossRef
Metadata
Title
Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series
Authors
Zhongjing Lin
Qiwei Hu
Yanlin Wu
Jianmin Xu
Qiong Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Keywords
Edema
Ranibizumab
Published in
BMC Ophthalmology / Issue 1/2019
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-019-1035-z

Other articles of this Issue 1/2019

BMC Ophthalmology 1/2019 Go to the issue

Case report

Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis

Research article

Open globe and penetrating eyelid injuries from fish hooks

Case report

Bone wax migrates to the orbit in a patient with a frontal sinus abnormality: a case report

Case report

Pediatric trochleitis associated with paranasal sinusitis: a case report

Research article

Changes in corneal endothelial density following scleral buckling surgery for rhegmatogenous retinal detachment: a retrospective cross-sectional study

Case report

Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy